Latest Breaking News On - University hospital of cologne germany - Page 1 : comparemela.com

Patients with chronic lymphocytic leukemia (CLL) experience long-term progression-free survival benefits with 1 year of venetoclax plus obinutuzumab versus a chemotherapy-based regimen.

United statesWilliamg wierdaOthman al sawafDrug administrationStudy groupUniversity of texas md anderson cancer centerUniversity hospital of cologne germanyEuropean hematology associationEuropean hematologyUniversity hospitalCancer centerCumulative illness rating scaleChronic lymphocytic leukemiaBiologic therapySkin cancerAlignant skin neoplasm